Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats

Table 1

Changes on the body weight (BW) and food and water intake in HFD-fed rats receiving 8-weeks treatment with myricetin or fenofibrate.

Variable (s)	RCD-fed	HFD-fed
	Vehicle	Vehicle	Myricetin (mg kg^−1 per day)			Fenofibrate
			75	150	300	(100 mg kg^−1 per day)
Initial BW (g rat^−1)	172.5±7.7	173.4±6.9	171.4±7.1	170.3±7.8	173.6±6.5	172.3±6.7
BW gain (g rat^−1)	17.8 ± 6.2^d	50.7 ± 7.0^b	41.4 ± 6.7^b	30.7 ± 6.9^a, c	23.6 ± 5.3^d	19.3 ± 5.5^d
Food intake (g rat^−1 per day)	19.3±5.9	20.3±6.7	19.8±6.5	20.7±6.6	20.3±7.8	19.9±7.1
Water intake (mL rat^−1 per day)	67.2 ± 8.1^c	88.3 ± 7.4^a	82.4±9.2^a	80.8±9.7^a	78.1±7.9^c	76.7 ± 8.9^c

Myricetin or fenofibrate was dissolved in distilled water for oral administration at the desired doses in a volume of 2 mL kg⁻¹ once a day into HFD-fed rats. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. All data represented as the mean ± SEM. ^aP <  .05 and ^b𝑃<.01 compared to the values of vehicle-treated RCD-fed rats in each group, respectively. ^c𝑃<.05 and ^d𝑃<.01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.